Cannabidiol (CBD) vaping continues to grow in popularity worldwide, driven by consumer demand for rapid effects and non-intoxicating cannabis alternatives. Yet public health agencies consistently emphasize that evidence on inhaled CBD remains limited compared to oral formulations.

This article reviews available statistics, regulatory data, and peer-reviewed findings from major health organizations.

1. CBD Use: What the Data Shows

According to survey data published in 2022–2024:

An estimated 26% of U.S. adults have tried CBD at least once (SingleCare survey, 2022).
Among CBD users, inhalation (including vaping) ranks among the fastest-growing consumption methods.
The global CBD market was valued at approximately $7–8 billion in 2023 and is projected to exceed $20 billion by 2028 (industry market analyses).

The U.S. National Institutes of Health (NIH) reports increasing public interest in cannabinoids, particularly for stress, sleep, and pain-related concerns.

National Institutes of Health

2. Pharmacokinetics: Why Vaping Works Faster

Route of administration significantly affects CBD absorption.

Peer-reviewed pharmacokinetic studies show:

Inhaled cannabinoids may reach peak plasma concentration within 3–10 minutes.
Oral CBD has reported bioavailability as low as 6–19% due to first-pass liver metabolism.
Inhalation may increase bioavailability to approximately 31–45%, depending on formulation and technique.

These findings explain why consumers report faster onset when vaping compared to oils or edibles.

However, faster absorption does not imply superior safety.

3. Safety Profile of CBD: What Is Known

The World Health Organization (WHO) concluded in its 2018 Expert Committee Report that:

“CBD exhibits no effects indicative of any abuse or dependence potential in humans.”

World Health Organization

Clinical trials studying oral CBD (particularly in epilepsy treatment) report that CBD is generally well tolerated. However, adverse effects observed in controlled studies include:

Fatigue
Diarrhea
Changes in appetite
Elevated liver enzymes at high doses

The FDA-approved CBD medication Epidiolex (oral formulation) demonstrated liver enzyme elevations in 5–20% of patients at higher therapeutic doses in clinical trials.

U.S. Food and Drug Administration

Important distinction: these safety data primarily involve oral CBD — not inhaled forms.

4. Lung Health & Vaping Risks

Respiratory safety became a major public health focus after the 2019 outbreak of EVALI (E-cigarette or Vaping-Associated Lung Injury).

The Centers for Disease Control and Prevention (CDC) reported:

2,807 hospitalized EVALI cases
68 confirmed deaths (as of February 2020)

Centers for Disease Control and Prevention

Vitamin E acetate — found mainly in illicit THC vape products — was strongly associated with these injuries.

While most EVALI cases involved THC rather than regulated CBD, the outbreak highlighted several concerns relevant to CBD vaping:

Aerosolized oils can affect lung tissue.
Heating may alter chemical structures.
Additives and flavoring agents may pose inhalation risks.

As of 2026, long-term epidemiological data on exclusive CBD vape use remains limited.

5. Regulatory Status & Oversight

CBD regulation varies internationally.

In the U.S.:

CBD derived from hemp (<0.3% THC) is federally legal under the 2018 Farm Bill.
The FDA has issued warning letters to companies making unapproved medical claims.
Inhaled CBD products are not FDA-approved treatments.

In Europe, the European Medicines Agency (EMA) emphasizes the need for additional safety evaluation before therapeutic claims can be supported.

European Medicines Agency

Regulatory agencies consistently stress:

Third-party laboratory testing
Accurate cannabinoid labeling
Absence of harmful additives
Compliance with THC limits

6. What Research Still Does Not Know

Major evidence gaps include:

Long-term respiratory outcomes of chronic CBD inhalation
Effects of repeated exposure to vaporized terpenes and flavoring agents
Standardized dosage measurement in vaping devices
Interaction risks when inhaled alongside prescription medications

A 2023 review in cannabis research literature concluded that while CBD itself appears to have a relatively favorable safety profile, inhalation introduces “additional toxicological considerations requiring further study.”

7. Risk–Benefit Perspective in 2026

Based on current evidence:

✔ CBD does not appear to produce intoxication or dependency.
✔ Inhalation provides rapid systemic absorption.
⚠ Long-term lung effects remain insufficiently studied.
⚠ Product quality significantly influences safety.

Public health authorities emphasize a precautionary approach until more longitudinal data becomes available.